Unassociated Document
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6 K
REPORT
OF
FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
EDAP
TMS
S.A. Files
Press
release EDAP Revises Termination Agreement with HealthTronics
July
16,
2007
EDAP
TMS
S.A.
Parc
Activite La Poudrette Lamartine
4/6
Rue
du Dauphine
69120
Vaulx-en-Velin - France
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F o
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
This
report on Form 6-K with respect to the Company's 2006 annual results, is hereby
incorporated by reference in the registration statement of EDAP TMS S.A. on
Form
F-3, file number 333-136811.
|
CONTACT:
EDAP TMS S.A.
|
Magnolia
Investor Relations
|
|
Blandine
Confort
|
Matt
Kreps
|
|
+33
4 78 26 40 46
|
972
801 4900
|
|
FOR
IMMEDIATE RELEASE
|
|
EDAP
Revises Termination Agreement with HealthTronics
Lyon,
France, July 16, 2007 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in
High
Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports
today
an update to its Termination Agreement with HealthTronics, Inc.
On
July
9, 2007, EDAP TMS S.A. entered into a letter agreement with HealthTronics
Inc,
pursuant to which the parties amended their Termination Agreement dated as
of
April 3, 2007.
The
letter agreement eliminated HealthTronics's obligation to pay EDAP any
additional amounts in excess of $600,000. In the prior agreement, HealthTronics
agreed to pay EDAP certain additional amounts in excess of $600,000 based
on a
formula related to the price at which HealthTronics resells the registered
200,000 EDAP shares. On July 3, 2007, EDAP withdrew its original Registration
Statement dated as of May 3, 2007 which reflected the prior terms of the
Termination Agreement. The company will file a new Registration Statement
on
July 16, 2007 reflecting the new terms of the agreement.
Under
the
new Termination Agreement, Healthtronics still agreed to pay EDAP TMS S.A
a
total of $600,000 within 60 days of effectiveness.
About
EDAP TMS S.A.
EDAP
TMS
S.A. develops and markets Ablatherm, the most advanced and clinically proven
choice for High Intensity Focused Ultrasound (HIFU) treatment of localized
prostate cancer. HIFU treatment is shown to be a minimally invasive and
effective treatment option with a low occurrence of side effects. Ablatherm-HIFU
is generally recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an alternative option,
or for patients who failed radiotherapy treatment. The company is also
developing this technology for the potential treatment of certain other types
of
tumors. EDAP TMS S.A. also produces and commercializes medical equipment
for
treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy
(ESWL).
For
more
information on the Company, contact Magnolia Investor Relations at (972)
801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or
see
the Company's Web sites at http://www.edap-tms.com and
http://www.hifu-planet.com.
To
sign
up for alerts please visit:
http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0
In
addition to historical information, this press release contains forward-looking
statements that involve risks and uncertainties. These include statements
regarding the Company's growth and expansion plans. Such statements are based
on
management's current expectations and are subject to a number of uncertainties
and risks that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may cause such
a
difference include, but are not limited to, those described in the Company's
filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment
is
in clinical trials but not yet FDA approved or marketed in the United
States.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date
:
July 16, 2007
EDAP
TMS
S.A.
| |
|
|
|
| /S/ MARC
OCZACHOWSKI |
|
|
|
MARC
OCZACHOWSKI |
|
|
|
| CHIEF EXECUTIVE OFFICER |
|
|
|